Purchase Order HHSF223201610289A
Award Date 7/30/16
Potential Completion Date 3/23/19
Potential Value $925K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Hayward, CA 94545, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The contract is for the delivery of a "HIGH-THROUGHPUT DESKTOP SEQUENCER WITH DATA ANALYSIS SYSTEM" and has a ceiling value of $426,000.30. There is no set-aside designation for this contract. Illumina has previously provided a range of sequencing systems, reagents, and...
- This is a $77,592.11 firm fixed price delivery order awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of genetic sequencing systems and reagents. The order is for the addition of items from Requisition #1168475, with no set-aside designation. Illumina has a history of providing sequencing instruments, reagents, and related services to support genomic research and diagnostics across various federal agencies, including the National Institutes of Health (NIH),...
- This is a firm fixed-price purchase order awarded by the Food and Drug Administration (FDA), a civilian federal agency, to Illumina, Inc., a for-profit manufacturer of genomic analysis technologies. The contract, with a ceiling value of $417,372.48, is for preventative maintenance services on Illumina's NextSeq 2000 and NextSeq 500 sequencing platforms. The award does not utilize a set-aside designation. Illumina is a leading provider of genetic sequencing instruments, reagents, and...
- This firm fixed-price purchase order was awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents, to provide a diagnostic check and system upgrades for the MiSeq Whole Genome Sequencer at six FDA laboratories. The $84,733.20 contract has a completion date of December 31, 2022 and was sole-sourced to Illumina due to the proprietary nature of the MiSeq technology. Illumina has previously provided sequencing systems,...
- This federal contract award by the Department of Health and Human Services Food and Drug Administration adds $110,510.96 in funding to an original requisition with Illumina, Inc., a manufacturer of genomic sequencing instruments and reagents. The contract is a firm fixed price Delivery Order with no set-aside designation. Illumina has previously provided sequencing systems, consumables, and support services to various government agencies for research and diagnostics. This award likely supports...
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for NEXTSEQ 500 comprehensive plan service maintenance for two NextSeq 500 sequencing systems at the FDA's location in Berwyn Heights, Maryland. The contract has a ceiling value of $265,801.32 and a period of performance through September 30, 2021. This contract does not have a...
- The Department of Health and Human Services Food and Drug Administration awarded a firm fixed price purchase order to Illumina, Inc., a manufacturer of genomic sequencing instruments and reagents, for the provision of a next generation sequencer. The contract has a potential value of $100,980.00 and a completion date of August 28, 2020. Illumina has provided similar sequencing systems and consumables to support genomic research and diagnostics across various federal agencies such as the National...
- This is a firm fixed price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies, for a service agreement for a NextSeq 500 instrument. The contract has a ceiling value of $185,733.00 and a period of performance through September 11, 2024. It does not utilize a set-aside designation. The contract appears to be part of Illumina's broader federal contracting portfolio, which...
- This is a firm fixed-price delivery order awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a for-profit manufacturer of genetic sequencing instruments and reagents. The $87,870.00 contract is for the provision of a MiSeq DNA sequencing system and related consumables. The award has no set-aside designation. Illumina has previously been awarded prime contracts and subcontracts by various federal agencies, including the National Institutes of Health (NIH), Centers for Disease...
- This is a $81,345.73 firm fixed price purchase order awarded by the Food and Drug Administration (FDA) to Illumina, Inc. for the supply of reagent kits to support high throughput DNA sequencing. The award does not have a set-aside designation. Illumina is a manufacturer of sequencing and array-based solutions for genetic and genomic analysis, and has previously provided sequencing systems, reagents, and services to support research and diagnostics across various federal agencies including the...